|
Protocol and Consent Forms
Modified: May 16, 2008
NOTE: Limited funding may be available to offset costs on certain protocols. Contact KCCOP for more information.
Bone Marrow Transplant
Also, see Cancer Control section for symptom
management/prevention trials.
CALGB C10001: Protocol Summary |
Donor Consent |
Recipient Consent
ALL, Ph+, complete remission after tx on CALGB 10102;
Sequential Chemo+Gleevec+Transplantation (QARC approval required for TBI)
CALGB 100104:
Protocol Summary |
Consent Form
MM, Durie-Salmon Stg >1, stable or responsive to >2 mos of any
induction therapy; Autologous
PBSCT → Maintenance CC-5013/placebo
TOP
Brain/CNS
Also, see Cancer Control section for symptom
management/prevention trials.
Glioma
RTOG 0627: Protocol Summary |
Consent Form
GLIOMA, glioblastoma multiforme or gliosarcoma, recur, prior RT & Temozolomide required;
Eval of Dasatinib
RTOG 0525: Protocol Summary |
Consent Form
GLIOMA, glioblastoma (includes gliosarcoma), supratentorial component, new dx; Conventional Adjuv Temozolomide vs Dose-Intens Temozolomide
MDA 2004-0662: Protocol Summary |
Consent Form
GLIOMA, glioblastoma multiforme, post-op or post-bx RT required; Temozolomide Alone vs Temozolomide in combination w/permutations of Thalidomide, Isotretinoin, &/or Celecoxib
Other
RTOG 0227: Protocol Summary |
Consent Form
CNS Lymphoma (Prim, B-cell, CD20+); Pre-RT Chemo (Methotrexate + Rituximab + Temozolomide) & Post-RT Temozolomide
Breast
Also, see Cancer Control section for symptom
management/prevention trials.
Stage 0
CTSU PACCT-1: Protocol Summary |
Consent Form
Adj., Stgs 0, I , Selected II, Hormone+, N0, Candidate for cytotoxic + hormonal therapy; Trial of Individualized Options for Tx (TAILORx Trial)
NSABP B-39: Protocol Summary |
Consent Form
Adj., Stg. 0, I, II; Conventional Whole Breast RT vs Partial Breast RT (Multi-Catheter, Mammosite, or 3D-CRT) (Sites need approval - check RT requirements in protocol.)
Stage I
CTSU PACCT-1: Protocol Summary |
Consent Form
Adj., Stgs 0, I , Selected II, Hormone+, N0, Candidate for cytotoxic + hormonal therapy; Trial of Individualized Options for Tx (TAILORx Trial)
NSABP B-42: Protocol Summary |
Randomization Consent |
Optional Registration Program Consent
Adj. or Neoadj., Stg I, II, IIIA (rcvd. neoadjuv chemo) or prim tumor T1-3
& ipsilateral nodes pN0-pN3b (rcvd. adjuv chemo), ER+ &/or PgR+, post-meno, completed 5 yrs Arom Inhib
or Tamox + AI; Letrozole vs placebo for prolonging survival
CTSU NCIC MA.27: Protocol Summary |
Consent Form
Adj., T1-3, Nx, N0-2 (N3 if >10 involved axillary nodes), M0, ER+ &/or PgR+, Post-meno; Exemestane vs Anastrozole
CALGB 40101: Protocol Summary |
Consent Form
Adj., T1‑4, N0-3, M0; Cyclophosphamide + Doxorubicin vs Paclitaxel
SWOG S0307: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Zoledronic Acid vs Clodronate vs Ibandronate (+ standard adjuv tx)
SWOG S0221: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Node+ or Hi-Risk
Node -, male pts allowed; Continuous Schedule Doxorubicin+Cyclophosphade+GCSF vs q2wk Doxorubicin+Cyclophosphade,
both →
Taxol
(q2wks vs weekly x 12 wks)
NSABP B-39: Protocol Summary |
Consent Form
Adj., Stg. 0, I, II; Conventional Whole Breast RT vs Partial Breast RT (Multi-Catheter, Mammosite, or 3D-CRT) (Sites need approval - check RT requirements in protocol.)
NSABP B-36: Protocol Summary |
Consent Form
Adj., T1-3N0M0; 5FU + Epirubicin + Cyclophosphamide vs Adriamycin + Cyclophosphamide
SWOG JMA.17R: Protocol Summary |
Consent Form
<2 yrs post-completion of aromatase inhibitor therapy,
disease-free; Letrozole vs placebo x 5 yrs
CTSU MA.27B: Protocol Summary |
Consent Form
MANDATORY Companion to MA.27; Bone Mineral Density study (Stratum A
closed to accrual.)
CTSU MA.27D: Protocol Summary |
Consent Form
MANDATORY Companion to MA.27; Breast Density, Plasma Hormone Chgs & Breast Ca Recur
Stage II
CTSU PACCT-1: Protocol Summary |
Consent Form
Adj., Stgs 0, I , Selected II, Hormone+, N0, Candidate for cytotoxic + hormonal therapy; Trial of Individualized Options for Tx (TAILORx Trial)
NSABP B-42: Protocol Summary |
Randomization Consent |
Optional Registration Program Consent
Adj. or Neoadj., Stg I, II, IIIA (rcvd. neoadjuv chemo) or prim tumor T1-3 &
ipsilateral nodes pN0-pN3b (rcvd. adjuv chemo), ER+ &/or PgR+, post-meno, completed 5 yrs Arom Inhib
or Tamox + AI; Letrozole vs placebo for prolonging survival
CTSU NCIC MA.27: Protocol Summary |
Consent Form
Adj., T1-3, Nx, N0-2 (N3 if >10 involved axillary nodes), M0, ER+ &/or PgR+, Post-meno; Exemestane vs Anastrozole
NSABP B-40: Protocol Summary |
Consent Form
Neoadj., T2-3, Nx/N0-cN2a, M0, HER2-; Capecitabine + Docetaxel or Gemcitabine
+ Docetaxel prior to AC +/- Bevacizumab (6 regimens) + Correlative Science
Studies → Surgery → Post-Op Bevacizumab (pre-op Bevacizumab regimens only)
CTSU ACOSOG Z1031: Protocol Summary |
Consent Form
Neoadj., T2-4c, any N, M0, Post-meno, ER+; 16-18 wks Exemestane vs Letrozole vs Anastrozole
SWOG S0307: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Zoledronic Acid vs Clodronate vs Ibandronate (+ standard adjuv tx)
SWOG S0221: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Node+ or Hi-Risk
Node -, male pts allowed; Continuous Schedule Doxorubicin+Cyclophosphade+GCSF vs q2wk Doxorubicin+Cyclophosphade, both →
Taxol
(q2wks vs weekly x 12 wks)
NSABP B-39: Protocol Summary |
Consent Form
Adj., Stg. 0, I, II; Conventional Whole Breast RT vs Partial Breast RT (Multi-Catheter, Mammosite, or 3D-CRT) (Sites need approval - check RT requirements in protocol.)
NSABP B-36: Protocol Summary |
Consent Form
Adj., T1-3N0M0; 5FU + Epirubicin + Cyclophosphamide vs Adriamycin + Cyclophosphamide
CALGB 40101: Protocol Summary |
Consent Form
Adj., T1‑4, N0-3, M0; Cyclophosphamide + Doxorubicin vs Paclitaxel
SWOG JMA.17R: Protocol Summary |
Consent Form
<2 yrs post-completion of aromatase inhibitor
therapy, disease-free; Letrozole vs placebo x 5 yrs
CTSU MA.27B: Protocol Summary |
Consent Form
MANDATORY Companion to MA.27; Bone Mineral Density study (Stratum A
closed to accrual.)
CTSU MA.27D: Protocol Summary |
Consent Form
MANDATORY Companion to MA.27; Breast Density, Plasma Hormone Chgs & Breast Ca Recur
Stage III
CALGB 40101: Protocol Summary |
Consent Form
Adj., T1‑4, N0-3, M0; Cyclophosphamide + Doxorubicin vs Paclitaxel
CTSU ACOSOG Z1031: Protocol Summary |
Consent Form
Neoadj., T2-4c, any N, M0, Post-meno, ER+; 16-18 wks Exemestane vs Letrozole vs Anastrozole
NSABP B-42: Protocol Summary |
Randomization Consent |
Optional Registration Program Consent
Adj. or Neoadj., Stg I, II, IIIA (rcvd. neoadjuv chemo) or prim tumor T1-3
& ipsilateral nodes pN0-pN3b (rcvd. adjuv chemo), ER+ &/or PgR+, post-meno, completed 5 yrs Arom Inhib
or Tamox + AI; Letrozole vs placebo for prolonging survival
CTSU NCIC MA.27: Protocol Summary |
Consent Form
Adj., T1-3, Nx, N0-2 (N3 if >10 involved axillary nodes), M0, ER+ &/or PgR+, Post-meno; Exemestane vs Anastrozole
SWOG S0307: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Zoledronic Acid vs Clodronate vs Ibandronate (+ standard adjuv tx)
SWOG S0221: Protocol Summary |
Consent Form
Adj., Stg I, II, III, Node+ or Hi-Risk
Node -, male pts allowed; Continuous Schedule Doxorubicin+Cyclophosphade+GCSF vs q2wk Doxorubicin+Cyclophosphade,
both →
Taxol
(q2wks vs weekly x 12 wks)
NSABP B-40: Protocol Summary |
Consent Form
Neoadj., T2-3, Nx/N0-cN2a, M0, HER2-; Capecitabine + Docetaxel or Gemcitabine
+ Docetaxel prior to AC +/- Bevacizumab (6 regimens) + Correlative Science
Studies → Surgery → Post-Op Bevacizumab (pre-op Bevacizumab regimens only)
CTSU MA.27B: Protocol Summary |
Consent Form
MANDATORY Companion to MA.27; Bone Mineral Density study (Stratum A
closed to accrual.)
CTSU MA.27D: Protocol Summary |
Consent Form
MANDATORY Companion to MA.27; Breast Density, Plasma Hormone Chgs & Breast Ca Recur
Recurrent/Metastatic
SWOG S0226: Protocol Summary |
Consent Form
Mets or Prog; Post-Menopausal; Anastrozole +/-
Fulvestrant as First-Line Therapy
TOP
Cancer Control
Cancer Control: Any Site
URCC U3905: Protocol Summary |
Consent Form
Standard tx completed 2-12 mos; Eval of Yoga for persistent sleep
disturbance
RTOG 0433: Protocol Summary |
Consent Form
Bone Mets; Single vs Multiple Fractions for Re-Irradiation
URCC U1902: Protocol Summary |
Consent Form
Any cancer dx, <1 prior chemo cycle & to
receive >3 more chemo cycles; Ginger vs placebo for nausea caused by
chemo
URCC U1701: Protocol Summary |
Consent Form
Any cancer dx, must receive chemo at least next 4 wks; Buspirone vs placebo to control dyspnea
Cancer Control: Breast
RTOG 0517: Protocol Summary |
Consent Form
BONE METS (from Breast, Lung, Prostate), must complete EBRT <14 days pre-regist, chemo or hormonal
therapy allowed; Zometa+Vit D+Ca +/- Single Dose Sr-89 or Sm-153
MDA 2005-0328: Protocol Summary |
Consent Form
BREAST or COLORECTAL, mets, planning to receive Capecitabine; Celecoxib for prevention of hand/foot syndrome
URCC U1105: Protocol Summary |
Consent Form
No prior chemo, planned Doxorubicin- or Epirubicin-containing regimen w/o
concurrent RT or IFN; 4 Double-blind regimens for preventing delayed nausea
CALGB 70301: Protocol Summary |
Consent Form
Companion Study to CALGB 40101; QOL, Employment & Informal Care Cost Analysis
Cancer Control: GI
MDA 2005-0328: Protocol Summary |
Consent Form
BREAST or COLORECTAL, mets, planning to receive Capecitabine; Celecoxib for prevention of hand/foot syndrome
NSABP LTS-01: Protocol Summary |
Consent Form
COLON or RECTAL, Pt reported outcomes in long-term survivors of C-05, C-06,
C-07, & R-02
Cancer Control: GU
RTOG 0517: Protocol Summary |
Consent Form
BONE METS (from Breast, Lung, Prostate), must complete EBRT <14 days pre-regist, chemo or hormonal
therapy allowed; Zometa+Vit D+Ca +/- Single Dose Sr-89 or Sm-153
RTOG 0518: Protocol Summary |
Consent Form
PROSTATE, Stgs I-IV (M0), Gleason/PSA dep, receiving concurrent RT & Long-Term LHRG Agonists; Zometa/placebo for Osteoporosis/Fx Prevention
SWOG S0437: Protocol Summary |
Consent Form |
Consent Form (Next-of-Kin)
PROSTATE, Long-Term followup for PCPT participants diagnosed w/Prostate Ca
Cancer Control: Gyn
GOG 0215: Protocol Summary |
Consent Form
Incr genetic risk of ovarian ca & electing risk-reducing surg (minimum removal of both ovaries); Zoledronic Acid vs Observ on Bone Mineral Density in Lumbar Spine
Cancer Control: Lung
RTOG 0517: Protocol Summary |
Consent Form
BONE METS (from Breast, Lung, Prostate), must complete EBRT <14 days pre-regist, chemo or hormonal
therapy allowed; Zometa+Vit D+Ca +/- Single Dose Sr-89 or Sm-153
SWOG E5597: Protocol Summary |
Consent Form
NSC, Resected Stage IA or IB; Selenium Supplementation as Chemoprevention
SWOG S0424: Protocol Summary | Consent Form
Molecular Epidemiology Study; NSCLC in Smoking & Non-Smoking Men/Women
Cancer Control: Lymphoma
SWOG 8819: Protocol Summary
(no consent form)
Path Companion to SWOG-coordinated protocols for prev untreated, NH
lymphoma
TOP
GIAlso, see Cancer Control section for symptom
management/prevention trials.
Colorectal
NSABP C-10: Protocol Summary |
Consent Form
COLON, Stg IV (Unresec) & synchronous asymptomatic prim tumor; 5FU + Leucovorin + Oxaliplatin + Bevacizumab
CALGB 80405: Protocol Summary |
Consent Form
COLORECTAL, Adenocarcinoma (Adv or Mets), Untreated; Either FOLFOX or FOLFIRI with either Bevacizumab or Cetuximab or w/combined Bevacizumab & Cetuximab
CTSU N0147: Protocol Summary |
Consent Form
COLORECTAL, Stg III, Post-Curative Resec; Oxal + 5FU /Leuc +/- Cetuximab
Esophagus
CALGB 80403: Protocol Summary |
Consent Form
ESOPHAGUS or GE Junction, Mets; ECF-C vs IC-C vs FOLFOX-C
SWOG S0356: Protocol Summary |
Consent Form
ESOPHAGUS or GE Junction, Stg II-III; Pre-Op Oxal+5FU & RT →
Surgery →
Post-op
Oxal+5FU (QARC Benchmark info required per site)
Rectal
NSABP R-04: Protocol Summary |
Consent Form
RECTAL, Stgs II-III, operable invasive adenocarcinoma; Pre-op RT + Capecitabine +/- Oxal vs Pre-op RT + CI 5-FU +/- Oxal (RNALater specimens required)
Stomach
CALGB 80101: Protocol Summary |
Consent Form
STOMACH or GE Junction, Post-Resection, Stg IB (if N1 or tumor exten beyond muscularis propria), II, IIIA-B, IV (w/M0); Eval
of 2 Chemoradiation Regimens (Rapid Review required - check RT requirements)
Other
CALGB 80403: Protocol Summary |
Consent Form
ESOPHAGUS or GE Junction, Mets; ECF-C vs IC-C vs FOLFOX-C
SWOG S0356: Protocol Summary |
Consent Form
ESOPHAGUS or GE Junction, Stg II-III; Pre-Op Oxal+5FU & RT →
Surgery →
Post-op
Oxal+5FU (QARC Benchmark info required per site)
CALGB 80101: Protocol Summary |
Consent Form
STOMACH or GE Junction, Post-Resection, Stg IB (if N1 or tumor exten beyond muscularis propria), II, IIIA-B, IV (w/M0); Eval
of 2 Chemoradiation Regimens (Rapid Review required - check RT requirements)
TOP
GUAlso, see Cancer Control section for symptom
management/prevention trials.
Prostate: Stage I
RTOG 0521: Protocol Summary |
Consent Form
PROSTATE, Localized Stgs I, II, III & select Stg IV (T4), High-Risk; Androgen Suppr + 3DCRT/IMRT +/- Docetaxel & Prednisone chemo (Sites need approval - check RT requirements in protocol.)
RTOG 0526: Protocol Summary |
Consent Form
PROSTATE, T1-T2c, Gleason 2-6 & PSA<20ng/ML or Gleason 7 &
PSA<10ng/mL, local recur post-EBRT; eval of Transperineal US-Guided
Brachytherapy (Sites need approval - see RT requirements in protocol.)
Prostate: Stage II
RTOG 0415: Protocol Summary |
Consent Form
PROSTATE, T1-2c, favorable risk; Hypofractionated vs Conventionally Fractionated 3D CRT/IMRT (Sites need approval - see RT requirements in protocol.)
RTOG 0521: Protocol Summary |
Consent Form
PROSTATE, Localized Stgs I, II, III & select Stg IV (T4), High-Risk; Androgen Suppr + 3DCRT/IMRT +/- Docetaxel & Prednisone chemo (Sites need approval - check RT requirements in protocol.)
RTOG 0526: Protocol Summary |
Consent Form
PROSTATE, T1-T2c, Gleason 2-6 & PSA<20ng/ML or Gleason 7 &
PSA<10ng/mL, local recur post-EBRT; eval of Transperineal US-Guided
Brachytherapy (Sites need approval - see RT requirements in protocol.)
RTOG 0232: Protocol Summary |
Consent Form
PROSTATE, T1c-2b, Nx/N0, M0; Ext Beam RT+Transperineal
Interstitial Permanent Brachytherapy vs Brachytherapy alone (Sites need approval - check RT requirements in protocol.)
RTOG 0612: Protocol Summary |
Consent Form
PROSTATE, Markers of RT Outcome for Pts Enrolled on RTOG 0232
RTOG 0126: Protocol Summary |
Consent Form |
Tissue Consent Form
PROSTATE, T1b-2b, Gleason 2-6 & PSA ≥10 & <20 or Gleason 7 & PSA <15; High- vs Standard-Dose 3D-CRT/IMRT
Prostate: Stage III
RTOG 0521: Protocol Summary |
Consent Form
PROSTATE, Localized Stgs I, II, III & select Stg IV (T4), High-Risk; Androgen Suppr + 3DCRT/IMRT +/- Docetaxel & Prednisone chemo (Sites need approval - check RT requirements in protocol.)
Prostate: Stage IV
SWOG S0421: Protocol Summary |
Consent Form
PROSTATE, Adenocarcinoma, Any T & N, M1b + bone mets, hormone refrac;
Docetaxel + Atrasentan vs Docetaxel + placebo
RTOG 0521: Protocol Summary |
Consent Form
PROSTATE, Localized Stgs I, II, III & select Stg IV (T4), High-Risk; Androgen Suppr + 3DCRT/IMRT +/- Docetaxel & Prednisone chemo (Sites need approval - check RT requirements in protocol.)
CALGB 90202: Protocol Summary |
Consent Form
PROSTATE, Adenocarcinoma, >1 bone met; Early vs
Standard Zoledronic Acid to prevent skeletal-related events
Prostate: Recurrent / Persistent /
Progressive
ID 00-156: Protocol Summary |
Consent Form
PROSTATE, Adenocarcinoma, androgen-indep, rising PSA; Induction Chemo →
Consolid Therapy +/- Strontium-89
Renal
CTSU E2805: Protocol Summary |
Consent Form
RENAL, Resectable, no distant mets; Double-blind adjuv Sunitinib vs Sorafenib vs placebo
TOP
GYN
Also, see Cancer Control section for symptom
management/prevention trials.
Cervical: Stage I
GOG 0219: Protocol Summary |
Consent Form
CERVICAL, Stgs I-B2, II-A (>4cm), II-B, III-B, IV-A, primary, untreated, squamous, adenocarcinoma, or adenosquamous; Weekly Cisp+RT vs Cisp+Tirapazamine+RT
RTOG 0418: Protocol Summary |
Consent Form
CERVICAL, Hysterectomy <7
wks pre-study entry, requiring chemoradiation; Pelvic IMRT +/- Chemo
RTOG 0417: Protocol Summary |
Consent Form
CERVICAL, Stgs IIB-IIIB or IB-IIA (if bx-proven pelvic
node mets &/or tumor >5cm), untreated; Bevacizumab + Definitive RT + Cisplatin
(Compliance review for GYN brachytherapy is required.)
Cervical: Stage II
GOG 0219: Protocol Summary |
Consent Form
CERVICAL, Stgs I-B2, II-A (>4cm), II-B, III-B, IV-A, primary, untreated, squamous, adenocarcinoma, or adenosquamous; Weekly Cisp+RT vs Cisp+Tirapazamine+RT
RTOG 0418: Protocol Summary |
Consent Form
CERVICAL, Hysterectomy <7 wks pre-study entry, requiring
chemoradiation; Pelvic IMRT +/- Chemo
RTOG 0417: Protocol Summary |
Consent Form
CERVICAL, Stgs IIB-IIIB or IB-IIA (if bx-proven pelvic
node mets &/or tumor >5cm), untreated; Bevacizumab + Definitive RT + Cisplatin
(Compliance review for GYN brachytherapy is required.)
Cervical: Stage III
GOG 0219: Protocol Summary |
Consent Form
CERVICAL, Stgs I-B2, II-A (>4cm), II-B, III-B, IV-A, primary, untreated, squamous, adenocarcinoma, or adenosquamous; Weekly Cisp+RT vs Cisp+Tirapazamine+RT
RTOG 0418: Protocol Summary |
Consent Form
CERVICAL, Hysterectomy <7 wks pre-study entry, requiring
chemoradiation; Pelvic IMRT +/- Chemo
RTOG 0417: Protocol Summary |
Consent Form
CERVICAL, Stgs IIB-IIIB or IB-IIA (if bx-proven pelvic
node mets &/or tumor >5cm), untreated; Bevacizumab + Definitive RT + Cisplatin
(Compliance review for GYN brachytherapy is required.)
Endometrial: Stage IIIGOG 0209: Protocol Summary |
Consent Form
ENDOMETRIAL, Stgs III-IV or Recur, no prior chemo; Doxo/Cisp/Taxol + G-CSF
vs Carbo/Taxol
Endometrial: Stage IVGOG 0209: Protocol Summary |
Consent Form
ENDOMETRIAL, Stgs III-IV or Recur, no prior chemo; Doxo/Cisp/Taxol + G-CSF
vs Carbo/Taxol
Endometrial: Advanced / Persistent / RecurrentGOG 0209: Protocol Summary |
Consent Form
ENDOMETRIAL, Stgs III-IV or Recur, no prior chemo; Doxo/Cisp/Taxol + G-CSF
vs Carbo/Taxol
GOG 0229F: Protocol Summary |
Consent Form
ENDOMETRIAL,
Recur or Persis, 1 prior chemotherapeutic regimen for endometrial
cancer required; Eval
of VEGF-Trap
Ovarian: Stage III
GOG 0218: Protocol Summary |
Consent Form
OVARIAN (Epith) or PERITONEAL (Prim), Stg III (any gross [macroscopic or
palpable] residual disease) or IV, Prev Untreated; 3 Arms: Each w/Carbo & Paclitaxel, in addition to Placebo vs Concurrent Bevacizumab →
Placebo vs Concurrent & Extended Bevacizumab
GOG 0212: Protocol Summary |
Consent Form
OVARIAN (Adv, Epith) or PERITONEAL (Prim), CR after Prim Platinum/Taxane chemo; Maint Chemo (12 monthly cycles of Paclitaxel or
CT-2103) vs No Tx until relapse
GOG 0235: Protocol Summary |
Consent Form
OVARIAN (Invasive, Epith), PERITONEAL (Prim), or
FALLOPIAN, Stgs III or IV, undergoing prim chemo; Longitudinal Study of YKL-40
Ovarian: Stage IV
GOG 0218: Protocol Summary |
Consent Form
OVARIAN (Epith) or PERITONEAL (Prim), Stg III (any gross [macroscopic or
palpable] residual disease) or IV, Prev Untreated; 3 Arms: Each w/Carbo & Paclitaxel, in addition to Placebo vs Concurrent Bevacizumab →
Placebo vs Concurrent & Extended Bevacizumab
GOG 0212: Protocol Summary |
Consent Form
OVARIAN (Adv, Epith) or PERITONEAL (Prim), CR after Prim Platinum/Taxane chemo; Maint Chemo (12 monthly cycles of Paclitaxel or
CT-2103) vs No Tx until relapse
GOG 0235: Protocol Summary |
Consent Form
OVARIAN (Invasive, Epith), PERITONEAL (Prim), or
FALLOPIAN, Stgs III or IV, undergoing prim chemo; Longitudinal Study of YKL-40
Vulvar
GOG 0205: Protocol Summary |
Consent Form
VULVAR, Locally Adv, Prev Untreated, Squamous; RT + Weekly
Cisplatin
Other
GOG 0235: Protocol Summary |
Consent Form
OVARIAN (Invasive, Epith), PERITONEAL (Prim), or
FALLOPIAN, Stgs III or IV, undergoing prim chemo; Longitudinal Study of YKL-40
TOP
Head & Neck
Also, see Cancer Control section for symptom
management/prevention trials.
CTSU E1302: Protocol Summary |
Consent Form |
Consent Form (if opting to continue tx
w/ZD1839)
Squamous, Mets or Locally Recur or PS 2, no
nasopharynx WHO 2 & 3; Docetaxel + ZD1839 or placebo
RTOG 0522: Protocol Summary |
Consent Form
OROPHARYNX, HYPOPHARYNX, LARYNX, Squamous, Selected Stgs III & IV; Concurrent Accelerated RT + Cisp +/- Cetuximab → Surg for selected pts (Sites need approval - check RT requirements in protocol.)
RTOG 0514: Protocol Summary |
Consent Form
Head & Neck Cancer Tissue/Specimen Bank
TOP
LeukemiaAlso, see Cancer Control section for symptom
management/prevention trials.
Acute
CALGB C10001: Protocol Summary |
Donor Consent |
Recipient Consent
ALL, Ph+, complete remission after tx on CALGB 10102;
Sequential Chemo+Gleevec+Transplantation (QARC approval required for TBI)
SWOG S0333: Protocol Summary |
Consent Form
ALL, Non-L3, New Dx, age <65; double Induction Chemo →
Consolid Chemo →
Maint Chemo
CTSU E2902: Protocol Summary |
Consent Form
AML, >2nd remission or remission after prim induction
failure or >age 60 in 1st remission; R115777 (Zarnestra) vs Observ
SWOG S0106: Protocol Summary |
Consent Form
AML (non-M3), DeNovo, age <61, no prior tx; Daunomycin
+ Ara-C +/- Mylotarg Induction
→ Ara-C Consolid
→ Post-Consolid Mylotarg or No
Additional Therapy
Chronic
CALGB 10404: Protocol Summary |
Consent Form
CLL
(B-cell), symptomatic & active intermediate or high-risk Rai staging, no prior
tx; Randomized study of 3 Fludarabine/Antibody combinations
CALGB 10501: Protocol Summary |
Consent Form
CLL (B-cell),
asymptomatic & untreated, <6 mos from initial flow cytometric
confirmation, IgVH unmutated subset; Early Tx vs Observation
w/Later Tx (both using Rituximab & Fludarabine)
SWOG S0325: Protocol Summary |
Consent Form
CML, in chronic phase, no prior tx; Imatinib vs Dasatinib
Ancillary
SWOG 9007: Protocol Summary |
Consent Form
MANDATORY Cytometry Companion to all Leukemia tx protocols
SWOG S9910: Protocol Summary |
Consent Form
Ancillary; specimen submission to Centralized Reference Lab & Tissue Repository
CALGB 8461: Protocol Summary |
Consent Form
Cytogenetics study for prev untreated AML, ALL, MDS
CALGB 9665: Protocol Summary |
Consent Form
Tissue Bank for prev untreated leukemia pts (acute or chronic) & MDS
CALGB 9760: Protocol Summary |
Consent Form
Multidrug Resistance studies for prev untreated AML & ALL
CALGB 9862: Protocol Summary |
Consent Form
Molecular Genetic study for ALL; MANDATORY for CALGB 19802 & its successors
TOP
LungAlso, see Cancer Control section for symptom
management/prevention trials.
NSC: Stage II
RTOG 0235: Protocol Summary |
Consent Form
NSC, Stgs IIB or III, inoperable, no diffuse bronchoalveolar; PET pre- & post-Definitive Chemoradiation
NSC: Stage IIIA - Unresectable
RTOG 0235: Protocol Summary |
Consent Form
NSC, Stgs IIB or III, inoperable, no diffuse bronchoalveolar; PET pre- & post-Definitive Chemoradiation
NSC: Stage IIIB
RTOG 0235: Protocol Summary |
Consent Form
NSC, Stgs IIB or III, inoperable, no diffuse bronchoalveolar; PET pre- & post-Definitive Chemoradiation
NSC: Stage IV
RTOG 0320: Protocol Summary |
Consent Form
NSC, 1-3 Brain Mets; Whole Brain RT+Stereotactic Radiosurgery +/- Temozolomide or Erlotinib
Ancillary
SWOG S9925: Protocol Summary
(no consent form)
Ancillary, Specimen Repository Companion
TOP
Lymphoma
Also, see Cancer Control section for symptom
management/prevention trials.
Non-Hodgkin's: Stage II
SWOG S0016: Protocol Summary | Consent Form
NH, Bulky Stg II or III-IV, Prev Untreated, Follicular, CD20+; CHOP +
Rituximab vs CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody
MDA 2004-0305: Protocol Summary | Consent Form
NH, B-Cell (incl. diffuse large B-Cell), >Stg II, aggressive, age >61, prev untreated; Rituximab-CHOP + Pegylated Liposomal Doxorubicin
SWOG S0515: Protocol Summary | Consent Form
NH, Bulky Stg II or III-IV diffuse large B-cell, prev untreated, CD20+, age >60; Standard Dose CHOP + Rituximab + Bevacizumab
Non-Hodgkin's: Stage III
SWOG S0016: Protocol Summary | Consent Form
NH, Bulky Stg II or III-IV, Prev Untreated, Follicular, CD20+; CHOP +
Rituximab vs CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody
MDA 2004-0305: Protocol Summary | Consent Form
NH, B-Cell (incl. diffuse large B-Cell), >Stg II, aggressive, age >61, prev untreated; Rituximab-CHOP + Pegylated Liposomal Doxorubicin
SWOG S0515: Protocol Summary | Consent Form
NH, Bulky Stg II or III-IV diffuse large B-cell, prev untreated, CD20+, age >60; Standard Dose CHOP + Rituximab + Bevacizumab
CTSU E4402: Protocol Summary | Consent Form
NH, Stg III-IV, Low Tumor Burden Indolent; Induc
Rituximab →
Rituximab (4 weekly doses vs Single dose q12wks)
Non-Hodgkin's: Stage IV
SWOG S0016: Protocol Summary | Consent Form
NH, Bulky Stg II or III-IV, Prev Untreated, Follicular, CD20+; CHOP +
Rituximab vs CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody
MDA 2004-0305: Protocol Summary | Consent Form
NH, B-Cell (incl. diffuse large B-Cell), >Stg II, aggressive, age >61, prev untreated; Rituximab-CHOP + Pegylated Liposomal Doxorubicin
SWOG S0515: Protocol Summary | Consent Form
NH, Bulky Stg II or III-IV diffuse large B-cell, prev untreated, CD20+, age >60; Standard Dose CHOP + Rituximab + Bevacizumab
CTSU E4402: Protocol Summary | Consent Form
NH, Stg III-IV, Low Tumor Burden Indolent; Induc
Rituximab →
Rituximab (4 weekly doses vs Single dose q12wks)
Non-Hodgkin's: Relapsed / Refractory
CALGB 50401: Protocol Summary | Consent Form
NH, Not Rituximab-refractory, Grade 1, 2, or 3a, Follicular; Lenalidomide vs Rituximab + Lenalidomide
SWOG S0520: Protocol Summary | Consent Form
B-Cell (diffuse large; high-grade Burkitt or Burkitt-like; prim mediastinal), Relapsed or Refrac, aggressive, not suitable for stem cell transp if 1st relapse; Eval of PXD101
Mantle Cell
SWOG S0601: Protocol Summary | Consent Form
Mantle Cell, Stg III-IV, Bulky Stg II, Prev Untreated; Combination
Rituximab-CHOP + Bortezomib induction therapy →
Bortezomib maintenance
Other
CALGB 50202: Protocol Summary | Consent Form
CNS, Prim, no NH, prev untreated; Intensive Chemo &
Immunotherapy
Ancillary
SWOG 8947: Protocol Summary | Consent Form
Serum Companion to SWOG-coord protocols for prev untreated, NH lymphoma
TOP
Myeloma
Also, see Cancer Control section for symptom
management/prevention trials.
SWOG S0120: Protocol Summary | Consent Form
MGUS, asymptomatic Myeloma, or Solitary Plasmacytoma, not requiring tx;
Observational Biologic Study (BM aspir & Perip Blood)
CALGB 100104:
Protocol Summary |
Consent Form
MM, Durie-Salmon Stg >1, stable or responsive to >2 mos of any
induction therapy; Autologous
PBSCT → Maintenance CC-5013/placebo
SWOG S0434: Protocol Summary | Consent Form
MM, Relapsed or Resistant; Eval of BAY 43-9006
SWOG S0309: Protocol Summary
Ancillary, Specimen Repository Protocol
TOP
|